CHROMADEX CORP (CDXC) Stock News

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

ChromaDex to Present at the 37th Annual Roth Conference

Insights into ChromaDex's Upcoming Earnings

CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ChromaDex (NASDAQ:CDXC) just reported results for the second quarter of 2024.Th...

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024

CDXC stock results show that ChromaDex missed on revenue for the second quarter of 2024.

Earnings Scheduled For March 4, 2025

Mentions: AMLX WEYS OLPX HRZN ...

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex to Participate in the 17th Annual LD Micro Main Event

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

ChromaDex Corporation Reports Second Quarter 2024 Financial Results